Nouscom

• Series D

  €120M

Sources: news.google.com

• XGEN Ventures

  Series D

• Versant Ventures

  Series D

• Panakès Partners

  Series D

• Indaco Venture Partners

  Series D

• EQT Life Sciences

  Series D

• CDP Venture Capital

  Series D

• Bpifrance

  Series D

• Andera Partners

  Series D

• 5AM Ventures

  Series D

• Intesa Sanpaolo Group

  Series D

• Neva SGR

  Series D

• Aurea

  Series D

• European Investment Bank

  Series D

• Angelini Ventures

  Series D

• Angelini Industries

  Series D

• Revelation Partners

  Series D, Lead

• M Ventures

  Series D, Lead

Sources: globenewswire.com

• Updates in the Molecular Biology and Personalized Management of Lynch Syndrome

  Consulting or advice, Fees or honoraria, Sep 18, 2026

• Exercise-associated epigenetic remodeling and TCR repertoire dynamics in Lynch syndrome carriers

  Consulting or advice, Grants or research support, Aug 28, 2026

Sources: pubmed.ncbi.nlm.nih.gov

• Fierce Biotech

• Nouscom raises €120 million in Series D for cancer prevention vaccine

  European Biotechnology Magazine

• Nouscom raises €120 million in an oversubscribed Series D round

  GlobeNewswire